Search

Caregiver’s attitudes, beliefs, and experiences for influenza vaccination in Australian children with medical comorbidities

Influenza vaccination recommendation by children’s hospital physicians and previous vaccine receipt in hospital was associated with vaccine uptake

Australian Aboriginal children have higher hospitalization rates for otitis media but lower surgical procedures than non-Aboriginal children

Aboriginal children and children from lower socio-economic backgrounds were over-represented with OM-related hospitalizations but had fewer TTIs

Morbidity due to acute lower respiratory infection in children with birth defects: A total population-based linked data study

Children with birth defects experience higher rates of hospitalisation for ALRIs before age 2 years than children with no birth defects.

Modelling the seasonality of respiratory syncytial virus in young children

The transmission dynamics of RSV infection among young children are still poorly understood and mathematical modelling can be used to better understand...

Prevalence of and risk factors for human rhinovirus infection in healthy aboriginal and non-aboriginal western australian children

Human rhinovirus (HRV) species C (HRV-C) have been associated with frequent and severe acute lower respiratory infections and asthma in hospitalized children.

Reduction in disparity for pneumonia hospitalisations between Australian indigenous and non-Indigenous children

In the 1990s pneumonia hospitalisation rates in Western Australia (WA) were 13 times higher in Indigenous children than in non-Indigenous children...

Hospitalisation for bronchiolitis in infants is more common after elective caesarean delivery

The authors previously reported an increased risk of hospitalisation for acute lower respiratory infection up to age 2 years in children delivered by...

Acute lower respiratory infections (ALRI) in Indigenous and non-Indigenous children

In Australia and many other developed countries, acute lower respiratory infection (ALRI) is one of the most common reasons for hospitalisation in young...

Modelling the impact of long-acting monoclonal antibody, maternal vaccine and hybrid programs of RSV immunisation in temperate Western Australia

Two RSV immunisations products: a maternal vaccine, Abrysvo, and a long-acting monoclonal antibody, nirsevimab, both designed to prevent RSV illness in infants, have recently become available. Modelling evidence is required to inform how to optimally use these products in immunisation programs to reduce the burden of RSV in young children.

Who is at risk of a respiratory syncytial virus hospitalisation? A linked, population-based birth cohort analysis in children aged less than 5 years

Respiratory syncytial virus (RSV) is a major cause of acute lower respiratory infections globally in children under five years. With the development of RSV prevention strategies, understanding risk factors and relation to age and population is useful for deciding the type of program implemented.